Mode
Text Size
Log in / Sign up
N/A Completed N=4,175

Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

Epilepsy · Postoperative Pain · Fibromyalgia · Post-market Surveillance
Source: ClinicalTrials.gov NCT01220180 ↗
Enrolled (actual)
4,175
Serious AEs
0.1%
Results posted
Dec 2011
Primary outcomePrimary: Percentage of Participants Achieving 28 Days Seizure Free Period in Intent-to Treat (ITT) Population — 66.30 Percentage of participants

Summary

This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants Achieving 28 Days Seizure Free Period in Intent-to Treat (ITT) Population
66.30 —
PRIMARY
Percentage of Participants Achieving 28 Days Seizure Free Period in Per Protocol (PP) Population
67.13 —
PRIMARY
Percentage of Participants With Improvement in Seizure Frequency in ITT Population
55.75; 28.57; 14.13; 1.55 —
PRIMARY
Percentage of Participants With Improvement in Seizure Frequency in PP Population
57.22; 29.39; 12.52; 0.87 —
PRIMARY
Change From Baseline in Daily Pain Score for NeP in ITT Population at Week 6
5.61; -3.02 <0.0001 sig
PRIMARY
Change From Baseline in Daily Pain Score for NeP in PP Population at Week 6
5.58; -3.02 <0.0001 sig
PRIMARY
Change From Baseline in Daily Pain Score for Fibromyalgia in ITT Population at Week 6
6.69; -3.37 <0.0001 sig
PRIMARY
Change From Baseline in Daily Pain Score for Fibromyalgia in PP Population at Week 6
6.69; -3.37 <0.0001 sig
SECONDARY
Change From Baseline in Sleep Interference Score for NeP in ITT Population at Week 6
4.25; -2.38 <0.0001 sig
SECONDARY
Change From Baseline in Sleep Interference Score for NeP in PP Population at Week 6
4.23; -2.37 <0.0001 sig
SECONDARY
Change From Baseline in Sleep Interference Score for Fibromyalgia in ITT Population at Week 6
6.43; -3.19 <0.0001 sig
SECONDARY
Change From Baseline in Sleep Interference Score for Fibromyalgia in PP Population at Week 6
6.41; -3.24 <0.0001 sig
SECONDARY
Number of Participants With Clinician's Global Impression of Change (CGIC) Scale for NeP in ITT Population
968; 1313; 671; 141; 7; 5 —
SECONDARY
Number of Participants With CGIC Scale for NeP in PP Population
956; 1306; 664; 140; 7; 5 —
SECONDARY
Number of Participants With Patient's Global Impression of Change (PGIC) Scale for NeP in ITT Population
1027; 1187; 686; 195; 5; 3 —
SECONDARY
Number of Participants With PGIC Scale for NeP in PP Population
1018; 1177; 680; 193; 5; 3 —
SECONDARY
Number of Participants With CGIC Scale for Fibromyalgia in ITT Population
30; 62; 21; 5; 0; 0 —
SECONDARY
Number of Participants With CGIC Scale for Fibromyalgia in PP Population
29; 62; 21; 5; 0; 0 —
SECONDARY
Number of Participants With PGIC Scale for Fibromyalgia in ITT Population
35; 61; 14; 8; 0; 0 —
SECONDARY
Number of Participants With PGIC Scale for Fibromyalgia in PP Population
34; 61; 14; 8; 0; 0 —

Eligibility Criteria

Inclusion Criteria

  • Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration

Exclusion Criteria

  • Non-consenting
  • Hypersensitivity to the active substance or to any of the excipients
  • galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01220180). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search